HOME >> BIOLOGY >> NEWS
Progress toward a more targeted treatment of Alzheimer's disease

Leuven, Belgium - Leuven Scientists from the Flanders Interuniversity Institute for Biotechnology (VIB) connected with the Catholic University of Leuven have shed a little more light on Alzheimer's disease. They've gone deeply into the operation of γ-secretase, a crucial factor in the origin of the disease. Their research has revealed that the action of γ-secretase is not homogeneous - as previously assumed - but quite differentiated. This discovery opens up perspectives for new medicines that will have fewer undesired side effects than current medicines do.

Alzheimer's disease
Alzheimer's disease, a degenerative disease that gradually and progressively destroys brain cells, affects between 50% and 70% of all cases of dementia and is therefore the major form of dementia. About 100,000 people suffer from this disease in Belgium. The damage caused to memory and mental functioning makes it one of today's most frightening syndromes. In particular, the first realization of the loss of any sense of reality is extremely difficult to accept. So, science continues to search feverishly for ways to treat the disease.

The role of γ-secretase
Alzheimer's disease involves a kind of plaque that forms in the brain cells. Several years ago, Bart De Strooper and other researchers deciphered the process by which the plaques originate. A major role in this process is played by γ-secretase, an enzyme that cuts proteins in a particular place. Sometimes the γ-secretase cleavage goes wrong, causing the creation of a by-product that sticks together and precipitates - thus forming the plaque. In their quest for new medicines, scientists are investigating this key role of ?-secretase to try to find substances that are able to block the formation of plaques. A thorough understanding of γ-secretase is therefore critical.

Diverse tissue-specific activity
γ-secretase is divided into several entitie
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Feb-2005


Page: 1 2

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress toward a targeted therapy for a specific form of leukemia
3. Progress against sarcoma
4. Progress toward artificial photosynthesis?
5. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
6. Progress in battle against life-threatening acute allergy
7. Progress report on Homogeneous Assay project
8. Progress being made in exploring potential use of stem cells to treat heart disease
9. Media Invite: Dinner to award prize for Progress in Cancer Research
10. Progress needed on global regime for access to genetic resources and benefit-sharing
11. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... Aug. 23, 2017  The general public,s help is being enlisted in ... that live in and on the human body –and are believed to ... The Microbiome Immunity Project ... microbiome, starting with the gut. The project's goal is to help advance ... IBM ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
Cached News: